drugset / Trial / NCT02212678
Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Phase 2
Completed
8 enrolled
University of Minnesota
Parkinson's Disease Society of the United Kingdom · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 3000 mg | Oral |